2-氯-3,5-二硝基吡啶 | 2578-45-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-氯-3,5-二硝基吡啶
• 英文名称: 2-chloro-3,5-dinitropyridine
• 英文别名: 3,5-dinitro-2-chloropyridine
• CAS: 2578-45-2
• 化学式: C₅H₂ClN₃O₄
• mdl: MFCD00006233
• 分子量: 203.542
• InChiKey: QLHVJBXAQWPEDI-UHFFFAOYSA-N

物化性质

• 熔点：
  63-65 °C(lit.)
• 沸点：
  320.9±37.0 °C(Predicted)
• 密度：
  2.2523 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• TSCA：
  Yes
• 危险等级：
  6.1
• 危险品标志：
  Xi,T
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R25
• WGK Germany：
  3
• 海关编码：
  2933 39 99
• 危险品运输编号：
  UN 2811 6.1/PG 2
• RTECS号：
  US6504750
• 包装等级：
  II
• 危险类别：
  6.1
• 危险性防范说明：
  P264,P270,P280,P301+P310+P330,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313
• 危险性描述：
  H300,H315,H319
• 储存条件：
  密封保存于2-8°C的阴凉干燥环境中。

SDS

Name:	2-Chloro-3 5-Dinitropyridine 99% Material Safety Data Sheet
Synonym:	None Known
CAS:	2578-45-2

Section 1 - Chemical Product MSDS Name:2-Chloro-3 5-Dinitropyridine 99% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2578-45-2	2-Chloro-3,5-Dinitropyridine	99%	219-937-3

Hazard Symbols: XI
Risk Phrases: 36/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May cause cardiac disturbances. May cause central nervous system depression. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May cause cardiac abnormalities. Can produce delayed pulmonary edema. Inhalation at high concentrations may cause CNS depression and asphixiation.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Containers may explode when heated. Non-combustible, substance itself does not burn but may decompose upon heating to produce irritating, corrosive and/or toxic fumes. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray to cool fire-exposed containers. For small fires, use dry chemical, carbon dioxide, or water spray. For large fires, use dry chemical, carbon dioxide, alcohol-resistant foam, or water spray.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2578-45-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: slightly yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 64.00 - 66.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H2ClN3O4
Molecular Weight: 203.54

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2578-45-2: US6504750 LD50/LC50:
CAS# 2578-45-2: Dermal, guinea pig: LD50 = >1 gm/kg; Oral, mouse: LD50 = 50 mg/kg; Oral, rat: LD50 = 50 mg/kg.
Carcinogenicity:
2-Chloro-3,5-Dinitropyridine - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/38 Irritating to eyes and skin.
Safety Phrases:
S 28A After contact with skin, wash immediately with
plenty of water.
WGK (Water Danger/Protection)
CAS# 2578-45-2: No information available.
Canada
CAS# 2578-45-2 is listed on Canada's NDSL List.
CAS# 2578-45-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2578-45-2 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3,5-二硝基吡啶 在 一水合肼 、 silver nitrate 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 以54.5%的产率得到3,5-二硝基吡啶
  参考文献：
  名称：

  3,5-吡啶A杂环间苯炔衍生物

  摘要：

  3,5-吡啶 (3) 是通过 3,5-二碘吡啶 (20) 和 3,5-二硝基吡啶 (21) 的快速真空热解生成的，并通过低温氩基质中的红外光谱表征。芳炔可以通过其在 254 nm 处的光稳定性与其他副产物清楚地区分，诱导快速开环，推测为 (Z)-1-aza-hex-3-ene-1,5-diyne。作为热解的副产物，HCN 和丁二炔以及痕量的乙炔、氰基乙炔、(E)-1-aza-hex-3-ene-1,5-diyne 和 3-iodo-5-pyridyl 自由基被鉴定出来（从 20）。已经通过密度泛函理论和 ab initio 量子化学方法在计算上探索了 3 和母体间苄 (1) 重排和断裂的几种途径。双自由基1和3的最低能量分解途径是伴随氢迁移的开环过程，导致(Z)-hex-3-ene-1,5-二炔[(Z)-10]和(Z)-分别为 3-aza-hex-3-ene-1,5-diyne [(Z)-24]。这两种反应都需要

  DOI：

  10.1021/ja039142u
• 作为产物：
  描述：

  2-羟基-5-硝基吡啶 在 硫酸 、 硝酸 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 2-氯-3,5-二硝基吡啶
  参考文献：
  名称：

  发射性萘啶衍生物的荧光性质和激基形成：用作胺的传感器。

  摘要：

  制备在1，5-氨基萘啶骨架上具有两个三氟甲基和Cl基的水溶性供体-受体型荧光团15Nap-Cl。荧光团15Nap-Cl显示出很强的溶剂化变色荧光，并且随着溶剂极性的增加，观察到一个红变色变化，伴随着荧光量子产率的增加。另外，在存在诸如乙胺，二乙胺和苯胺之类的胺的情况下，观察到荧光中进一步显着的红移。密度泛函计算将荧光行为的来源确定为15-Nap-Cl与相应胺之间的激基复合物形成。利用荧光行为来制造可以识别各种伯，仲和叔胺的传感器。

  DOI：

  10.1002/chem.201903643
• 作为试剂：
  描述：

  (+/-)-methyl 4-cyano-5-methyl-4-phenylhexanoate 在 sodium hydroxide 、 2-氯-3,5-二硝基吡啶 作用下， 以 四氢呋喃 、 吡啶 、 水 为溶剂， 生成 (+/-)-propyl 4-cyano-5-methyl-4-phenylhexanoate
  参考文献：
  名称：

  Enantioselective synthesis of (2S)-5-{4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl}-2-isopropyl-2-phenyl-pentanenitrile dihydrochloride (E2050) using enzyme-catalyzed kinetic resolution

  摘要：

  Immobilized lipase (Pseudomonas sp.)-catalyzed transesterification of (RS)-4-cyano-4-isopropyl-4-phenyl-1-butanol 4 in vinyl acetate gave (S)-4-cyano-4-isopropyl-4-phenyl-1-butyl acetate 3a with high enantiomeric excess values and conversions (95-97% ee, 30-47%, E = 90-93), leaving the enantiomerically pure (R)-alcohol 4 (>99% ee) unreacted. As 3a can be efficiently converted to E2050, use of the immobilized lipase should provide an economical route for large-scale synthesis of E2050. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(02)00364-6

文献信息

• Chemokine receptor binding heterocyclic compounds
  申请人：AnorMED, Inc.

  公开号：US06750348B1

  公开（公告）日：2004-06-15

  This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1 to R7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6 alkyl; R8 is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″ group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6 alkyl group, (3) a C0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6 alkylamino or C3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

  这项发明涉及一类新型的杂环化合物，它们结合趋化因子受体，抑制其天然配体的结合。这些化合物通过结合趋化因子受体，包括CXCR4和CCR5，从而抑制这些趋化因子的后续结合，产生对HIV感染的保护效果。本发明提供了一个式I的化合物 其中，W是氮原子，Y不存在，或者W是碳原子，Y═H； R1至R7可以相同也可以不同，并且独立地选择自氢或直链、支链或环状的C1-6烷基； R8是一个取代的杂环基或取代的芳香基 Ar是一个芳香或杂芳环，每个环在单个或多个非连接位置可选择地取代有电子给体或吸引体基团； n和n′独立地为0-2； X是下式的一个基团： 其中，环A是一个可选择地取代的饱和或不饱和的5或6元环，P是一个可选择地取代的碳原子、一个可选择地取代的氮原子、硫或氧原子。环B是一个可选择地取代的5到7元环。上述式中的环A和环B可以通过基团V从任何位置连接到基团W，其中V是一个化学键，一个(CH2)n″基团（其中n″=0-2）或一个C═O基团。Z是(1)一个氢原子，(2)一个可选择地取代的C1-6烷基基团，(3)一个用可选择地取代的芳香或杂环基团取代的C0-6烷基基团，(4)一个可选择地取代的C0-6烷基氨基或C3-7环烷氨基基团，(5)一个可选择地取代的羰基或磺酰基。这些化合物还包括任何药学上可接受的酸盐和金属络合物，以及它们的任何立体异构体形式和立体异构体形式的混合物。
• Electron-Deficient Heteroarenium Salts: An Organocatalytic Tool for Activation of Hydrogen Peroxide in Oxidations
  作者：Jiří Šturala、Soňa Boháčová、Josef Chudoba、Radka Metelková、Radek Cibulka

  DOI：10.1021/jo502865f

  日期：2015.3.6

  prepared and tested as simple catalysts of oxidations with hydrogen peroxide, using sulfoxidation as a model reaction. Their catalytic efficiency strongly depends on the type of substituent and is remarkable for derivatives with an electron-withdrawing group, showing reactivity comparable to that of flavinium salts which are the prominent organocatalysts for oxygenations. Because of their high stability

  制备了一系列的单取代的嘧啶鎓和吡嗪鎓三氟甲磺酸酯和3,5-二取代的吡啶鎓三氟甲磺酸酯，并使用硫氧化作为模型反应，对过氧化氢的简单氧化催化剂进行了测试。它们的催化效率在很大程度上取决于取代基的类型，并且对于具有吸电子基团的衍生物而言是显着的，其反应性与黄酮盐相当，后者是氧合作用的主要有机催化剂。由于它们的高稳定性和良好的可及性，4-（三氟甲基）嘧啶鎓和3,5-二硝基吡啶鎓三氟甲磺酸盐是选择的催化剂，并显示出催化脂肪族和芳香族硫化物氧化为亚砜的作用，定量转化率高，制备产率高，并且具有优异的性能。化学选择性。K R +值（p K R + <5）和较小的负还原电位（E red > -0.5 V）。在催化氧化过程中原位形成的过氧化氢加合物充当底物氧化剂。通过在B3LYP / 6-311 ++ g（d，p）水平上的计算获得的从这些杂环氢过氧化物到硫代苯甲醚的转移的吉布斯自由能表明，它们是比烷基氢过氧化
• Triazole-Substituted Nitroarene Derivatives: Synthesis, Characterization, and Energetic Studies
  作者：Nagarjuna Kommu、Vikas D. Ghule、A. Sudheer Kumar、Akhila K. Sahoo

  DOI：10.1002/asia.201300969

  日期：2014.1

  series of dense and energetic polynitroaryl‐1,2,4‐triazoles were synthesized through the nitration of aryl‐1,2,4‐triazoles. The Cu‐catalyzed/base‐mediated coupling reactions of haloarenes with 1,2,4‐triazoles delivered N‐aryl‐1,2,4‐triazoles. These new nitro‐rich‐aryltriazoles were characterized by analytical and spectroscopic methods. The solid‐state structures of most of these compounds were established

  通过芳基1,2,4,3-三唑的硝化反应，合成了一系列致密而高能的聚硝基芳基1,2,4-三唑。卤代芳烃与1,2,4-三唑的Cu催化/碱介导的偶联反应提供了N-芳基1,2,4-三唑。这些新的富含硝基的芳基三唑通过分析和光谱方法进行了表征。这些化合物大多数的固态结构是通过X射线衍射分析确定的。它们的热性质通过差示扫描量热法-热重分析法确定。还计算了它们的形成热（HOF）和晶体密度。合成化合物的密度为1.40至1.85 g cm -3。这些新合成的化合物中的一些表现出高正HOF，良好的热稳定性，高密度以及合理的爆速和压力。
• Lewis Acidic Boranes, Lewis Bases, and Equilibrium Constants: A Reliable Scaffold for a Quantitative Lewis Acidity/Basicity Scale
  作者：Robert J. Mayer、Nathalie Hampel、Armin R. Ofial

  DOI：10.1002/chem.202003916

  日期：2021.2.24

  borane/Lewis base combination through the sum of two descriptors, one for Lewis acidity (LAB) and one for Lewis basicity (LBB). The resulting Lewis acidity/basicity scale is independent of fixed reference acids/bases and valid for various types of trivalent boron‐centered Lewis acids. It is demonstrated that the newly developed Lewis acidity/basicity scale is easily extendable through linear relationships with

  基于三芳基硼烷与各种以 O、N、S 和 P 为中心的路易斯碱在二氯甲烷中反应的 90 个实验平衡常数，开发了针对以硼为中心的路易斯酸的定量路易斯酸度/碱度标度。 20℃。使用线性自由能关系 log  K B = LA B + LB B进行分析，可以通过两个描述符（一个用于路易斯酸度 ( LA B )）的总和来计算任何类型的硼烷/路易斯碱组合的平衡常数K B。一个用于路易斯碱度（LB B）。所得的路易斯酸度/碱度标度与固定的参考酸/碱无关，并且对于各种类型的三价硼中心路易斯酸有效。事实证明，新开发的路易斯酸度/碱度标度可以通过与量子化学计算或常见的物理有机描述符和已知热力学数据（Δ H ）的线性关系轻松扩展。此外，该实验平台可用于硼烷催化反应的合理发展。
• [EN] BRD4-JAK2 INHIBITORS<br/>[FR] INHIBITEURS DE BRD4-JAK2
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2020051572A1

  公开（公告）日：2020-03-12

  Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

  本文披露了一些抑制BDR4的化合物及其在癌症治疗中的应用。还披露了筛选BDR4选择性抑制剂的方法。在某些方面，披露了公式I至IV的化合物。

表征谱图